HC Wainwright reissued their buy rating on shares of Vical Incorporated (NASDAQ:VICL) in a research report report published on Tuesday. The firm currently has a $6.00 price target on the biotechnology company’s stock.

VICL has been the subject of several other reports. ValuEngine cut Vical from a sell rating to a strong sell rating in a report on Friday, September 1st. Ifs Securities reiterated an outperform rating on shares of Vical in a report on Tuesday, August 8th. Finally, Zacks Investment Research cut Vical from a hold rating to a sell rating in a report on Thursday, October 26th. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $7.50.

Shares of Vical (NASDAQ:VICL) opened at $1.90 on Tuesday. Vical has a fifty-two week low of $1.66 and a fifty-two week high of $3.70.

Vical (NASDAQ:VICL) last issued its earnings results on Monday, October 23rd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The company had revenue of $3.24 million for the quarter, compared to analysts’ expectations of $3.60 million. Vical had a negative net margin of 92.13% and a negative return on equity of 29.06%. sell-side analysts forecast that Vical will post -1 EPS for the current year.

In other Vical news, Director Robert C. Merton acquired 85,700 shares of the company’s stock in a transaction on Friday, November 10th. The stock was acquired at an average price of $1.75 per share, for a total transaction of $149,975.00. Following the acquisition, the director now owns 95,451 shares in the company, valued at approximately $167,039.25. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 5.98% of the company’s stock.

A hedge fund recently raised its stake in Vical stock. New York State Common Retirement Fund increased its position in Vical Incorporated (NASDAQ:VICL) by 83.6% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 130,706 shares of the biotechnology company’s stock after purchasing an additional 59,504 shares during the quarter. New York State Common Retirement Fund owned approximately 1.18% of Vical worth $354,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 20.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/hc-wainwright-reiterates-buy-rating-for-vical-incorporated-vicl/1725330.html.

About Vical

Receive News & Ratings for Vical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.